Biogen Idec, GNS target personalized medicine
Using a patient dataset and high-horsepower computing, researchers at Biogen Idec and analytics company GNS Healthcare have built a rheumatoid arthritis disease model that lets them run patient-specific virtual clinical trials, according to Fierce Biotech IT. This personalized-medicine stepping stone yields dynamic disease models of individualized patient outcomes.
The model generates predictions of the RA-sufferer's response to drugs, and the response to inhibiting drug targets and disease pathways. That's a first, said Colin Hill, CEO at GNS.
The collaborators used a patient dataset comprising genotyping, whole-blood gene expression profiles and such clinical measures as tender joints, swollen joints and C-reactive protein. They fed the data into GNS's supercomputer-driven platform, REFS (reverse-engineering and forward-simulation). REFS built the model.